AbbVie CEO Robert A. Michael to Become Chairman in 2025

By Tamara Parker • Friday, February 14 10:23 • Permanent Link

AbbVie (NYSE: ABBV) has announced significant changes to its board of directors, with Chief Executive Officer (CEO) Robert A. Michael set to assume the additional position of Chairman effective July 1, 2025. This follows the retirement of Richard A. Gonzalez, who had been serving as Chairman since the company's formation in 2013.

Robert A. Michael, who has been with the company for over 32 years, has held various leadership roles, including President and Chief Operating Officer before becoming CEO. He has been integral to AbbVie's success and growth, having been responsible for global commercial operations, finance, corporate human resources, global operations, business development, and corporate strategy.

Gonzalez, the outgoing Chairman and former CEO, expressed his confidence in Michael and the board to successfully lead AbbVie into the future, continuing to deliver groundbreaking medicines for patients and creating value for shareholders.

In addition to the change in leadership, Glenn F. Tilton will also retire from AbbVie's board effective July 1, 2025.

AbbVie's mission is to discover and deliver innovative medicines and solutions that address serious health issues today and in the future, with a focus on therapeutic areas such as immunology, oncology, neuroscience, and eye care, as well as products and services in their Allergan aesthetics portfolio. The market has reacted to these announcements by moving the company's shares 0.7% to a price of $194.8. For the full picture, make sure to review AbbVie's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.